VICTORIA, BC , Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX ), a clinical-stage biotechnology company leveraging its proprietary DiffuSphereTM technology to optimize drug delivery for applications with significant unmet need, today announced the recent appointments of Chief Scientific Officer Amanda Malone , as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development.
"These appointments strengthen and round out our senior leadership team as we continue to advance the DiffuSphereTM technology, co-developed by Dr. Malone, into increasingly later-stage clinical settings," said Dr. James Helliwell , CEO of Eupraxia.
"Dr. Sarugaser's scientific background combined with his healthcare and capital markets experience and relationships, make him an ideal addition to the team to support our ongoing corporate leadership and growth. In his analyst coverage of Eupraxia, he developed a deep understanding of our science, business and growth opportunity enabling a strong strategic approach to our development.
Dr Malone is a dedicated, innovative and passionate leader who has been at the forefront of our highly successful R&D initiatives since Eupraxia's inception. We are excited to have her apply her considerable skillset to our business operations as a whole." Background on Amanda Malone Dr.
Malone co-founded Eupraxia with Dr. Helliwell in 2012 and built Eupraxia's .
